- Treatment options for non-small cell lung stage III cancer2021 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Diagnostic and therapeutic guidelines for stage III non-small-cell lung cancer2016 | Faculty of Medicine in Pilsen
- The role of durvalumab in the treatment of stage III NSCLC2020 | First Faculty of Medicine
- Advances in management of stage III non-small cell lung cancer2022 | First Faculty of Medicine
- Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience2020 | First Faculty of Medicine
- Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe2020 | First Faculty of Medicine
- Strategies for the treatment of patients with non-small cell lung cancer stage III2016 | First Faculty of Medicine
- Direct costs of adjuvant oncology treatment of colorectal carcinoma stage III- difference between peroral and parenteral agent2012 | Faculty of Medicine in Pilsen
- Evaluating the Effect of Conservative Therapy in Patients with Wilkes Stage III Temporomandibular Joint Derangement2021 | First Faculty of Medicine
- Efficacy and toxicity of ciplatin and vinorelbine in the treatment of stage III non-small cell lung cancer2000 | Faculty of Medicine in Hradec Králové
- Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer2023 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer2020 | First Faculty of Medicine
- Does arthroscopic lysis and lavage in subjects with Wilkes III internal derangement reduce pain?2021 | First Faculty of Medicine
- Long-term results of two different neoadjuvant vinorelbine and cisplatin regiments in stage III non-small cell lung cancerPublication without faculty affiliation
- Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival2021 | Central Library of Charles University
- Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria2022 | Third Faculty of Medicine
- Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 2382023 | Third Faculty of Medicine
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial2014 | Third Faculty of Medicine
- Inoperable stage III non-small cell lung cancer treated by weekly paclitaxel/carboplatin chemotherapy with concurrent radiotherapyPublication without faculty affiliation
- Correlations among expression of Ki-67, p53 hormonal receptors and traditional clinico-pathological characteristics of advanced stage III and IV breast cancer +1Publication without faculty affiliation
- MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial2018 | Publication without faculty affiliation
- Endometriosis in reproductive immunology2002 | Faculty of Medicine in Pilsen
- Pembrolitzumab in the treatment of NSCLC2017 | Publication without faculty affiliation
- Adjuvant durvalumab after successful concomitant chemoradiotherapy of non-small cell lung cancer treatment2021 | Faculty of Medicine in Pilsen
- Ovarian cancer resection and debulking in the upper abdomen2019 | First Faculty of Medicine
- Growth factors and breast tumors, comparison of selected growth factors with traditional tumor markers2011 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Extended lung resection2003 | First Faculty of Medicine
- Durvalumab in the treatment of locally advanced unresectable non‑small cell lung cancer – case report2023 | First Faculty of Medicine, Third Faculty of Medicine
- Capecitabin e and oxaliplatin (XELOX) in adjuvant therapy of colorectal cancer. Results of the NO16968 (XELOXA) trial2010 | First Faculty of Medicine
